{"id":"NCT03096847","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer","officialTitle":"A National Phase IIIb, Multi-center, Open Label Study for Women and Men With Hormone-receptor Positive, HER-2 Negative Locally Advanced or Metastatic Breast Cancer Treated With Ribociclib (LEE011) in Combination With Letrozole","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-10-24","primaryCompletion":"2018-12-11","completion":"2020-02-06","firstPosted":"2017-03-30","resultsPosted":"2021-05-19","lastUpdate":"2021-10-11"},"enrollment":502,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Advanced Metastatic Breast Cancer"],"interventions":[{"type":"DRUG","name":"ribociclib","otherNames":["LEE011"]},{"type":"DRUG","name":"letrozole","otherNames":[]},{"type":"DRUG","name":"goserelin","otherNames":[]}],"arms":[{"label":"ribociclib + letrozole cohort A","type":"EXPERIMENTAL"},{"label":"ribociclib + letrozole cohort B1","type":"EXPERIMENTAL"},{"label":"ribociclib + letrozole cohort B2","type":"EXPERIMENTAL"}],"summary":"This was a national, multi-center, open-label, phase IIIb trial to determine the efficacy and safety of treatment with ribociclib (LEE011) plus letrozole in patients with HR+, HER2-negative advanced (recurrent or metastatic) breast cancer. Patients were treated with daily doses of 600 mg ribociclib (3-weeks-on/1-week-off schedule) in combination with 2.5 mg letrozole daily (continuous dosing). Dose adjustments (dose reduction or interruption) according to safety findings were allowed.","primaryOutcome":{"measure":"Clinical Benefit Rate (CBR) in Women and Men With Hormone Receptor Positiv, HER-2 Negative Breast Cancer Treated With Ribocilib and Letrozole","timeFrame":"At 24 weeks after last patient enrolled in trial","effectByArm":[{"arm":"Ribociclib + Letrozole Cohort A","deltaMin":63.2,"sd":null},{"arm":"Ribociclib + Letrozole Cohort B1","deltaMin":57.7,"sd":null},{"arm":"Ribociclib + Letrozole Cohort B2","deltaMin":56.5,"sd":null},{"arm":"Total","deltaMin":60.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":84,"countries":["Germany"]},"refs":{"pmids":["34953442"],"seeAlso":["https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=729"]},"adverseEventsSummary":{"seriousAny":{"events":97,"n":319},"commonTop":["NEUTROPENIA","NAUSEA","FATIGUE","ALOPECIA","NASOPHARYNGITIS"]}}